JPRN-UMIN000045492Completed未知
Prospective study on evaluation of immune response after SARS-CoV-2 vaccination - Prospective study on evaluation of immune response after SARS-CoV-2 vaccination
Shionogi & Co., Ltd.0 sites143 target enrollmentStarted: September 16, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 143
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Participants who have been confirmed to have a history of SARS-CoV-2 infection. 2. A loss of > 200 mL of whole blood or blood components within 12 weeks or > 100 mL within 4 weeks of the first dose of study intervention in male participants. A loss of > 200 mL of whole blood or blood components within 16 weeks or > 100 mL within 4 weeks of the first dose of study intervention in female participants. 3. Current enrollment or past participation within the last 30 days before signing of ICF in any other clinical study involving an clinical study or any other type of medical research. 4. Participants who have been confirmed to be positive in human immunodeficiency virus (HIV) antigen/antibody test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody test result.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code: P13UK) - P13UKPrevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia and pneumonia.EUCTR2010-023865-22-GBHealth Protection Agency
Completed
Phase 4
Responses to booster vaccinations in UK toddlersISRCTN84763401Health Protection Agency (UK)200
Completed
Not Applicable
Prospective study on evaluation of immunological response after SARS-CoV-2 vaccinatioCOVID-19JPRN-UMIN000045097Shionogi & Co., Ltd.205
Completed
Unknown
A study for evaluating the immune response by ingestion of fermented plant extractHealthy adultJPRN-UMIN000052021EP Mediate Co., Ltd.36
Completed
Not Applicable
A study for evaluating the immune response by ingestion of a fucoidan-containing food in adult males and females : a randomized, double blind, placebo-controlled, parallel-group trialJPRN-UMIN000024995TTC Co., Ltd.60